TRODELVY IS DESIGNED TO WORK DIFFERENTLY THAN TRADITIONAL CHEMOTHERAPIES
What TRODELVY is made of
Trodelvy is a type of drug called an antibody-drug conjugate, or ADC for short. Unlike traditional chemotherapy, ADCs contain 3 parts: an antibody, an anti-cancer drug, and a linker.
Looks for a specific protein, in this case Trop-2, which is found to be overexpressed in many cancers, including bladder cancer
B. Anti-cancer drug
B Anti-cancer drug
Kills cancer cells once they’re found
Connects the anti-cancer drug to the antibody
HOW TRODELVY IS THOUGHT TO ATTACK BLADDER CANCER TUMORS
Scientists discovered that patients with bladder cancer have tumor cells that more often contain the Trop-2 protein. TRODELVY binds to cells with Trop-2.
Information from laboratory studies suggest that this is how TRODELVY works. The clinical benefit of these observations is unknown.
The antibody in TRODELVY finds and sticks to the Trop-2 protein
Once attached, TRODELVY delivers an anti-cancer drug directly into the bladder cancer cells
TRODELVY kills the bladder cancer cells from within.
Trodelvy is the first ADVANCED BLADDER CANCER TREATMENT
to target THE Trop-2 PROTEIN